Start with the naming: mazdutide, IBI362, and LY3305677
Mazdutide is the international nonproprietary name for a long-acting, acylated peptide developed to activate both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Earlier publications and trial records often call the same development compound IBI362 or LY3305677. FDA's substance record maps those names to one defined molecular identity and lists the identifier MB76Z4IBZ5.
The shared names do not make every material sold as mazdutide equivalent. Clinical studies used sponsor-manufactured investigational or approved products with defined composition, release testing, formulation, and storage controls. A research-vendor lot is a separate test article whose sequence, modification, content, impurities, and stability must be established from its own records.
Mazdutide is also not a synonym for semaglutide, tirzepatide, retatrutide, or native oxyntomodulin. Those molecules overlap in parts of their biological rationale but differ in sequence, chemical modification, receptor profile, and clinical evidence. This article reviews mazdutide as a research subject; it does not provide a protocol, dose, route, treatment recommendation, or evidence that any supplier product is suitable for human or veterinary use.
- Mazdutide: the current nonproprietary name
- IBI362 and LY3305677: development codes used in publications and trial records
- Target profile: dual GLP-1 and glucagon receptor agonism
- Research-vendor material: a separately documented lot that cannot inherit a clinical product's evidence or regulatory status
Molecular identity includes the modification, not only the peptide backbone
FDA's Global Substance Registration System describes mazdutide as a modified peptide with a fatty-acid-containing side chain attached through a linker. That architecture is part of the substance identity. A catalog name or backbone sequence alone is therefore incomplete: the attachment site, linker, acyl group, terminal chemistry, and declared counterion all affect the expected molecular mass and analytical behavior.
The design is related to oxyntomodulin, an endogenous peptide that can signal through GLP-1 and glucagon receptors. Mazdutide is not simply purified oxyntomodulin. Its substitutions and acylation were introduced to create a distinct, longer-acting development compound. Results obtained with native oxyntomodulin or another dual agonist should not be attributed automatically to mazdutide.
For analytical review, molecular identity should be connected to a full structural specification and an observed result. Mass spectrometry can support the expected molecular form, while peptide mapping or another orthogonal method can strengthen sequence and modification-site evidence. A chromatographic purity percentage alone cannot identify the main peak.
Receptor and cell evidence: dual activity is supported, but assay context matters
In sponsor-reported preclinical work, LY3305677 bound and activated human and mouse GLP-1 and glucagon receptors. The same program reported glucose-dependent insulin secretion in isolated mouse islets. These experiments support the intended dual-receptor mechanism and provide a bridge between molecular design and downstream metabolic signals.
The evidence is mechanistic rather than clinical. Receptor assays can differ in receptor density, species, readout, cell background, exposure time, and reference ligand. Apparent potency in an engineered cell line does not establish what will occur in an intact organism, and an islet response does not establish a durable clinical outcome.
The early receptor report was published as a conference abstract rather than a full peer-reviewed methods paper. It is useful primary evidence, but the limited methodological detail reduces independent assessment of assay validation, comparators, and reproducibility. That limitation should remain visible when the mechanism is summarized.
Animal evidence separates the two receptor contributions only partially
The same preclinical program studied the compound in diet-induced obese mice and reported lower food intake, greater energy expenditure, improved glucose tolerance, and reduced body weight under the tested conditions. Experiments in receptor-knockout models suggested that both GLP-1R and GCGR signaling contributed to the observed effects rather than one receptor accounting for the entire phenotype.
Those models are valuable because they test a causal receptor hypothesis, but they remain simplified. Mouse receptor pharmacology, energy balance, diet, housing, and exposure can differ materially from human physiology. Knockout models also introduce lifelong adaptations that may change the response being measured.
Animal findings should therefore be described as model-specific support for the dual-agonist rationale. They do not establish human effectiveness, long-term safety, or the identity and activity of a commercial research lot.
Early human studies established a signal, not a final answer
Small phase 1b studies in participants with overweight or obesity and in participants with type 2 diabetes examined short-term pharmacology, tolerability, and exploratory metabolic outcomes. These studies reported body-weight and glycemic changes alongside gastrointestinal adverse events. They helped justify larger controlled trials and supplied initial information about repeated exposure to the sponsor's formulation.
Phase 1 studies are not designed to settle broad benefit-risk questions. The samples were small, the observation periods were short, and participant selection was narrow. Exploratory endpoints can identify a signal, but they are more vulnerable to chance, missing data, and design choices than a prespecified primary outcome in a larger randomized trial.
It is also important to keep the product boundary intact. Human exposure to a clinical-development formulation does not demonstrate the purity, quantity, sterility, endotoxin status, or stability of a separate material carrying the same name.
Phase 2 obesity research showed dose-related weight change over 24 weeks
A randomized, double-blind phase 2 trial in China enrolled 248 adults with overweight or obesity. At 24 weeks, the published mean body-weight changes across the three mazdutide groups were approximately minus 6.7 percent, minus 10.4 percent, and minus 11.3 percent, compared with plus 1.0 percent for placebo. More participants in the mazdutide groups reached categorical weight-loss thresholds.
The trial supports a controlled human efficacy signal for the studied product and population. It does not show that every receptor effect observed in animals contributed equally, and it does not isolate the glucagon-receptor component from the GLP-1 component. The trial was relatively short for a chronic outcome and was conducted in one country, so duration and generalizability remained open questions.
Adverse events were predominantly gastrointestinal, and the publication reported higher event frequency in active-treatment groups than with placebo. These observations describe monitored trial participants; they are not a safety specification for unrelated material and cannot be converted into unsupervised-use guidance.
Phase 3 obesity trials strengthened the human evidence
GLORY-1, a randomized phase 3 trial in China, enrolled 610 adults with overweight or obesity. At the prespecified 32-week analysis, mean body-weight change was about minus 10.1 percent and minus 12.6 percent in the two mazdutide groups, compared with plus 0.5 percent for placebo. The proportions reaching at least 5 percent weight loss were 73.9 percent and 82.0 percent, versus 10.5 percent with placebo.
GLORY-2 extended the evidence to 461 adults with moderate to severe obesity. At week 60, the mean body-weight change was minus 16.65 percent with mazdutide and minus 1.50 percent with placebo; 84.3 percent and 33.1 percent, respectively, reached at least 5 percent weight loss. Gastrointestinal events remained the most common adverse-event category, and treatment discontinuation due to adverse events was uncommon but higher with mazdutide.
These trials provide substantially stronger evidence than cell, animal, or phase 1 studies because they were randomized, controlled, and designed around prespecified clinical outcomes. They still do not answer every question. Sponsor involvement, participant selection, trial duration, regional enrollment, discontinuations, and missing-data assumptions all affect interpretation, while longer-term cardiovascular and other clinical outcomes require their own studies.
The 2026 U.S. phase 2 trial adds geographic evidence, with limitations
A randomized U.S. phase 2 trial enrolled 179 adults with obesity or overweight plus at least one related complication. Across the active groups, mean body-weight change at the main 32-week analysis ranged from approximately minus 7.3 percent to minus 18.1 percent, compared with minus 0.9 percent for placebo. Gastrointestinal events were common, and discontinuation was highest in the most intensive study group.
This trial is useful because it broadens the evidence beyond the earlier China-centered program and tests the sponsor's compound in a different participant population. It was still a phase 2 study with a modest sample and a 48-week total duration. Between-group differences and exposure-response patterns should be interpreted within the prespecified analysis plan rather than treated as a universal ranking of regimens.
A U.S. clinical trial is not the same as U.S. approval. Trial authorization permits a defined investigation; it does not mean FDA has concluded that the product is safe and effective for marketing.
Type 2 diabetes trials support glycemic activity, not universal equivalence
A 250-participant randomized phase 2 trial in type 2 diabetes reported mean glycated-hemoglobin reductions ranging from about 1.4 to 1.7 percentage points at 20 weeks, compared with little change on placebo. Body weight also decreased in the active groups. Larger phase 3 trials subsequently compared mazdutide with placebo or an active GLP-1 receptor agonist and reported significant glycemic improvement together with greater body-weight reduction under the tested conditions.
The active-comparator trial is especially informative because it asks whether the defined mazdutide product performs differently from an established comparator rather than only from placebo. Even so, noninferiority or superiority on glycated hemoglobin and body weight does not establish superiority on every clinical outcome, and it does not resolve long-term cardiovascular, renal, hepatic, or rare safety questions.
Results from obesity and diabetes populations should not be pooled without qualification. Baseline disease, background medication, endpoints, estimands, and follow-up differ. A responsible evidence map keeps each trial attached to its population and prespecified outcome.
Regulatory status depends on jurisdiction
Innovent disclosed through the Hong Kong Stock Exchange that China's National Medical Products Administration approved mazdutide for chronic weight management in June 2025 and subsequently approved a type 2 diabetes indication. Those are product- and jurisdiction-specific decisions. They do not turn a bulk research material into the approved Chinese medicine, and they do not create approval in other countries.
As reviewed on November 10, 2026, mazdutide is not FDA approved in the United States. FDA's current public material describes mazdutide products marketed to consumers under 'research' labels as unapproved drugs, and FDA warning letters have specifically addressed mazdutide marketing. FDA's mazdutide substance record also states that the existence of a UNII does not imply regulatory review or approval.
Three records must therefore remain separate: a substance-identity entry, permission to conduct a clinical trial, and marketing approval for a specific finished product. None establishes the quality or lawful intended use of an unrelated supplier lot.
What the evidence establishes—and what remains unresolved
The evidence is strongest for a defined dual-receptor development compound, reproducible metabolic effects in animal models, and clinically meaningful changes in body weight and glycemic endpoints in multiple randomized human trials. The phase 3 program materially advances the evidence beyond early mechanistic studies.
Unresolved questions include long-term outcomes, uncommon adverse events, durability after the trial period, performance across broader populations, the independent contribution of glucagon-receptor signaling, and comparative outcomes against newer dual- and triple-agonist programs. Some of these questions require larger or longer trials rather than additional receptor assays.
The program also illustrates an evidence-stage principle: positive randomized outcomes can support conclusions about the sponsor's characterized product without validating every molecule sold under the same name. Scientific evidence and lot-specific quality evidence remain complementary, not interchangeable.
- Cell and receptor evidence: supports dual GLP-1R/GCGR activity under defined assay conditions
- Animal evidence: supports a mechanistic and metabolic signal in specific models
- Human evidence: multiple randomized trials support weight and glycemic effects for sponsor-controlled products
- Regulatory evidence: product-specific approvals exist in China; no FDA approval exists in the United States as of the review date
- Not established: equivalence, safety, or suitability of a research-vendor lot
Supplier documentation answers a different question
A trial publication can establish what a characterized clinical product did in a study. It cannot establish what is in a supplier's current vial. Supplier documentation should connect a specific lot to a complete structural claim, identity evidence, chromatographic composition, quantitative content, and a justified stability statement. Sterility and endotoxin are separate attributes requiring separate methods when those claims are made.
Mazdutide presents more analytical complexity than an unmodified short peptide. The specification should identify the peptide sequence, substitutions, terminal groups, linker, acyl chain, attachment site, and counterion. The expected mass should correspond to the complete molecular form, not just an unmodified backbone. A mass match can support identity, while a purity chromatogram describes detected components under the stated method; neither substitutes for a calibrated content assay.
Acylated peptides can also present solubility, adsorption, aggregation, and degradation questions that depend on formulation and container. A general handling statement is not a stability study. Useful stability evidence names the actual formulation, concentration, container, conditions, time points, analytical procedures, and acceptance criteria.
A research-procurement checklist for mazdutide
Use the literature to define the molecule and experimental question, then evaluate each offered lot on its own documentation. Record missing evidence as not established rather than assuming pass or fail. Compare suppliers only after confirming that the listings describe the same molecular form and amount.
A polished certificate, high area percentage, or reference to clinical trials cannot close a broken traceability chain. The useful review question is narrower: which attributes were measured, by which methods, on which identified sample, with what results and limits?
- Naming: are mazdutide, IBI362, and LY3305677 mapped to one explicit structural specification?
- Structure: are sequence, substitutions, linker, acyl chain, attachment site, termini, and counterion disclosed?
- Identity: do observed mass or orthogonal data agree with the complete claimed molecular form?
- Purity and content: are chromatographic area and quantitative peptide amount reported as different measurements?
- Traceability: do product, lot, sample, report, laboratory, and test dates match?
- Stability: are claims supported for the actual formulation, container, conditions, and time points?
- Scope: are chemical tests kept separate from sterility, endotoxin, and any claim of clinical equivalence?
FAQ: Is mazdutide the same as tirzepatide or retatrutide?
No. Mazdutide is designed to activate GLP-1 and glucagon receptors. Tirzepatide activates GIP and GLP-1 receptors, while retatrutide is designed to activate GIP, GLP-1, and glucagon receptors. They are different molecules with different modifications, receptor profiles, development programs, and regulatory records. Evidence for one should not be assigned to another.
FAQ: Is mazdutide FDA approved?
No. As of November 10, 2026, mazdutide is not FDA approved in the United States. Company filings report product-specific approvals in China, but approval is jurisdiction-specific. An FDA UNII substance entry, an investigational trial, or an approval in another country does not create U.S. marketing approval.
FAQ: Do mazdutide trials validate research-supplier products?
No. Clinical trials evaluate defined products made and controlled for those programs. Their findings cannot establish the identity, purity, quantity, sterility, stability, safety, or suitability of an unrelated supplier lot. Lot-specific analytical documentation and scientific literature answer different questions.
Sources and further reading
Primary and standards-based sources used to frame this educational overview:
- FDA Global Substance Registration System: mazdutide identity record and UNII
- Coskun et al. (2021): receptor, islet, and mouse-model pharmacology of LY3305677
- Jiang et al. (2021): phase 1b mazdutide study in adults with overweight or obesity
- Ji et al. (2022): phase 1b mazdutide study in type 2 diabetes
- Ji et al. (2023): randomized phase 2 mazdutide trial in type 2 diabetes
- Jiang et al. (2024): randomized phase 2 mazdutide trial in adults with overweight or obesity
- Ji et al. (2025): GLORY-1 phase 3 obesity trial
- GLORY-2 investigators (2026): phase 3 trial in moderate to severe obesity
- Rosenstock et al. (2026): randomized U.S. phase 2 mazdutide obesity trial
- Phase 3 placebo-controlled mazdutide trial in type 2 diabetes
- Phase 3 mazdutide versus dulaglutide trial in type 2 diabetes
- ClinicalTrials.gov: GLORY-2 trial record NCT06124807
- Innovent Hong Kong Stock Exchange filing: China regulatory approvals for mazdutide
- FDA: concerns with unapproved GLP-1 drugs, including mazdutide sold under research labels
Explore related resources
Peptide Due Diligence Research Brief
Keep the evidence in view.
Receive concise briefings on analytical testing, documentation quality, supplier transparency, and new additions to the research library.
By subscribing, you agree to receive PDD research emails. Unsubscribe at any time.
Already subscribed? Get your free field guide.